Midmichigan Medical Offices-beaverton Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 439 S Ross St, Beaverton, MI 48612 Phone: 989-246-3500 Fax: 989-246-3519 |
Beaverton Medical Center P.c. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 129 W Brown St, Beaverton, MI 48612 Phone: 989-435-2937 Fax: 989-435-3121 |
Family Health & Wellness Pc Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 129 W Brown St, Beaverton, MI 48612 Phone: 989-435-2937 Fax: 989-435-3121 |
Mymichigan Medical Center Gladwin Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 439 South Ross Street, Beaverton, MI 48612 Phone: 989-246-3500 Fax: 989-246-3519 |
News Archive
Aerospace giant Boeing tested two kinds of ionization technologies — like those widely adopted in schools hoping to combat covid — to determine how well each killed germs on surfaces and decided that neither was effective enough to install on its commercial planes.
The Contraceptive Pill celebrated its 50th birthday on Mother's Day this year. The Pill was approved by the FDA in 1960 giving greater control to women about when they would like to give birth. The choice was supposed to help eliminate unwanted pregnancies and help couples grow closer. It was also supposed to help the couple financially by not placing burdens of early children on them.
Menopause- that time in every woman's life when the ovaries no longer release an egg each month and menstruation ceases forever- is a rare thing among Earth's infinitely varied creatures.
In an effort to protect children from harmful tobacco smoke exposure, health and medical professionals are pushing for a ban on smoking in public housing in a report appearing in this week's New England Journal of Medicine.
BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.
› Verified 6 days ago